Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Allergan, Paratek Pharma report positive results in late-stage trial of acne treatment Shares of Allergan Plc and Paratek Pharmaceuticals Inc. PRTK, +10.73% rose premarket Monday, after the companies reported positive results for a trial of a treatment for moderate to severe acne. The companies said two Phase 3 trials of sarecycline met their primary endpoints. Allergan is planning to seek U.S. Food and Drug Administration approval for the drug in the second half. "Sarecycline is a narrow spectrum antibiotic, which we believe can offer meaningful clinical benefits for patients afflicted with acne," Paratek Chief Medical Officer Evan Loh said in a statement. Paretek shares rose 11% premarket, while Allergan was up 0.3%.
Shares of Paratek Pharmaceuticals ($PRTK) have spiked higher in pre-market trading after the biopharmaceutical company reported positive results from a late-stage study of its drug to treat patients with community-acquired bacterial pneumonia.
